Medication Use Patterns Associated with Spirometry in Diagnosing COPD

REFERENCES

• National Heart Lung and Blood Institute. Morbidity & Mortality: 2007 Chart Book on Cardiovascular, Lung, and Blood Diseases. National Heart Lung and Blood Institute. 2007, Editor
   Google Scholar
• Han M K, Kim M G, Mardon R, Renner P, Sullivan S, Diette G B, Martinez F J. Spirometry utilization for COPD: How do we measure up?. Chest 2007; 132(2)403–409
   PubMed Web of Science ®Google Scholar
• Lee T A, Bartle B, Weiss K B. Spirometry use in clinical practice following diagnosis of COPD. Chest 2006; 129(6)1509–1515
   PubMed Web of Science ®Google Scholar
• Badgett R G, Tanaka D J, Hunt D K, Jelley M J, Feinberg L E, Steiner J F, Petty T L. The clinical evaluation for diagnosing obstructive airways disease in high-risk patients. Chest 1994; 106(5)1427–1431
   PubMed Web of Science ®Google Scholar
• Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004; 125(4)139–149
   Google Scholar
• Straus S E, McAlister F A, Sackett D L, Deeks J J. Accuracy of history, wheezing, and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease. J Gen Intern Med 2002; 17(9)684–688
   PubMed Web of Science ®Google Scholar
• van Schayck C P, van Weel C, Harbers H J, van Herwaarden C L. Do physical signs reflect the degree of airflow obstruction in patients with asthma or chronic obstructive pulmonary disease?. Scand J Prim Health Care 1991; 9(4)232–238
   PubMedGoogle Scholar
• Straus S E, McAlister F A, Sackett D L, Deeks J J. The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease. JAMA 2000; 283(14)1853–1857
   PubMed Web of Science ®Google Scholar
• Holleman D R, Jr., Simel D L. Does the clinical examination predict airflow limitation?. JAMA 1995; 273(4)313–319
   PubMed Web of Science ®Google Scholar
• National Committee for Quality Assurance (NCQA), HEDIS. Health plan employer data & information set, Vol. 2, Technical specifications. 2005. National Committee for Quality Assurance (NCQA), Washington, DC 2006; 350
   Google Scholar
• American Thoracic Society and European Respiratory Society. Standards for the diagnosis and management of patients with COPD. 2004, (cited 2007 December 28); Available from: http://www.thoracic.org/sections/copd/resources/copddoc.pdf
   Google Scholar
• Celli B R, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur RespirJ 2004; 23(6)932–946
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Updated 2007), (cited 2007 December 16); Available from: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989
   Google Scholar
• Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br MedJ 2000; 320(7245)1297–1303
   PubMed Web of Science ®Google Scholar
• Calverley P M, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, Yates J C, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8)775–789
   PubMed Web of Science ®Google Scholar
• Donohue J F, van Noord J A, Bateman E D, Langley S J, Lee A, Witek T J, Jr., Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1)47–55
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen R A, Carson S S, Lohr K N. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4(3)253–262
   PubMed Web of Science ®Google Scholar
• Jones P W, Bosh T K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155(4)1283–1289
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26)1902–1909
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, Anthonisen N R. Inhaled corticosteroids and mortality in COPD. Chest 2006; 130(3)640–646
   PubMed Web of Science ®Google Scholar
• Ram F S, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003; 58(7)580–584
   PubMed Web of Science ®Google Scholar
• Ramirez-Venegas A, Ward J, Lentine T, Mahler D A. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112(2)336–340
   PubMed Web of Science ®Google Scholar
• Rennard S I, Anderson W, Zu Wallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(5)1087–1092
   PubMed Web of Science ®Google Scholar
• Stockley R A, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61(2)122–128
   PubMed Web of Science ®Google Scholar
• Stockley R A, Whitehead P J, Williams M K. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 2006; 7: 147
   PubMed Web of Science ®Google Scholar
• van Noord J A, Aumann J L, Janssens E, Verhaert J, Smeets J J, Mueller A, Cornelissen P J. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129(3)509–517
   PubMed Web of Science ®Google Scholar
• Wadbo M, Lofdahl C G, Larsson K, Skoogh B E, Tornling G, Arwestrom E, Bengtsson T, Strom K. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur RespirJ 2002; 20(5)1138–1146
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26)1902–1909
   PubMed Web of Science ®Google Scholar
• Alsaeedi A, Sin D D, McAlister F A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113(1)59–65
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez A V, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176(2)162–166
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(2)144–149
   PubMed Web of Science ®Google Scholar
• Lee T A, Weiss K B. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169(7)855–859
   PubMed Web of Science ®Google Scholar
• Dales R E, Vandemheen K L, Clinch J, Aaron S D. Spirometry in the primary care setting: influence on clinical diagnosis and management of airflow obstruction. Chest 2005; 128(4)2443–2447
   PubMed Web of Science ®Google Scholar
• Walker P P, Mitchell P, Diamantea F, Warburton C J, Davies L. Effect of primary-care spirometry on the diagnosis and management of COPD. Eur RespirJ 2006; 28(5)945–952
   PubMed Web of Science ®Google Scholar
• Rubin D B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127(8 Pt 2)757–763
   PubMed Web of Science ®Google Scholar
• Barr R G, Celli B R, Martinez F J, Ries A L, Rennard S I, Reilly J J, Jr., Sciurba F C, Thomashow B M, Wise R A. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005; 118(12)1415
   PubMedGoogle Scholar
• Bolton C E, Ionescu A A, Edwards P H, Faulkner T A, Edwards S M, Shale D J. Attaining a correct diagnosis of COPD in general practice. Respir Med 2005; 99(4)493–500
   PubMed Web of Science ®Google Scholar
• Kaminsky D A, Marcy T W, Bachand M, Irvin C G. Knowledge and use of office spirometry for the detection of chronic obstructive pulmonary disease by primary care physicians. Respir Care 2005; 50(12)1639–1648
   PubMedGoogle Scholar
• Walters J A, Hansen E, Mudge P, Johns D P, Walters E H, Wood-Baker R. Barriers to the use of spirometry in general practice. Aust Fam Physician 2005; 34(3)201–203
   PubMedGoogle Scholar
• Joo M J, Lee T A, Weiss K B. Geographic variation in chronic obstructive pulmonary disease exacerbation rates. J Gen Intern Med 2007; 22(11)1560–1565
   PubMed Web of Science ®Google Scholar